24/7 Market News Snapshot 14 August, 2025 – Traws Pharma, Inc. Common Stock (NASDAQ:TRAW)

August 14, 2025

DENVER, Colo., 14 August, 2025 (www.247marketnews.com) – (NASDAQ:TRAW) are discussed in this article.
Traws Pharma, Inc. (TRAW) has experienced significant trading activity, with shares opening at $1.697 and currently showing a strong gain of approximately 9.94%, trading at $1.803. This upward movement follows a previous session close of $1.640 and is supported by a trading volume of 622.37K, indicating increased investor interest. Key technical indicators suggest that the stock may be breaking through resistance levels, and market participants are advised to monitor this bullish trend for potential continuation patterns, particularly in light of volume fluctuations that could signal shifts in sentiment.

In parallel, Traws Pharma has made notable advancements in its efforts to combat pandemic-level respiratory viruses, particularly through the development of its antiviral candidates ratutrelvir for COVID-19 and Tivoxavir marboxil (TXM) for influenza. The company has prioritized ratutrelvir, a novel, ritonavir-free protease inhibitor aimed at treating acute COVID-19 and Long COVID. Traws has submitted a study proposal to the Human Research Ethics Committee (HREC) to commence Phase 2 clinical trials, evaluating ratutrelvir’s safety and efficacy against current treatments, which addresses the critical need for effective antiviral therapies, particularly for patients ineligible for other options.

Furthermore, Traws is advancing the development of TXM, a promising single-dose antiviral for seasonal flu and H5N1 bird flu, while also engaging with public health authorities to consider it for pandemic preparedness initiatives. Recent preclinical data highlights TXM’s potential effectiveness, emphasizing its public health significance.

Iain D. Dukes, Interim CEO of Traws, stated, “We are committed to advancing our antiviral therapies that respond to real-world health challenges. These innovative treatments not only present significant market opportunities but also aim to establish new standards of care, particularly for vulnerable populations.” As awareness of respiratory viruses grows, Traws intends to keep stakeholders updated through upcoming business updates, underscoring its dedication to developing patient-focused antiviral solutions.

Related news for (TRAW)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.